In particular, the IP2-induced nischarin-derived epitope TNQDFIQRL (TL9) was shown to be immunogenic and to induce tumor growth defect in vivo when targeted in peptide vaccines in combination with IP2 (Figs. 6 and 7). The gene discussed is IKBKG; the disease is neoplasm.